Deep Tech Startups

BI Foresight publishes briefings and analysis on emerging technologies, covering topics such as quantum computing and artificial intelligence and how they are shaped by systems integration.

1 investor

Big Bang Boom is an Indian defence technology company that develops systems for defence forces, governments, and strategic partners, including anti-drone defence, armored vehicle situational awareness, and non-lethal interdiction systems. Founded in 2019, it is an iDEX-recognized startup that exports defence systems internationally.

1 investor

Bilix develops therapeutics using a proprietary PEGylated bilirubin platform (BRIXELLE) aimed at anti-inflammatory and anti-cancer drug applications, as well as contrast agents for cancer diagnostics and theranostics. The company targets intractable inflammatory diseases and cancer through drug delivery and diagnostic products.

1 investor

BinaryTech develops technology and an IoT tech stack for scaling Massive IoT, connecting large numbers of devices over 5G networks. The company works with telecom operators worldwide on deploying and testing their networks.

1 investor

Binaural DSP works on digital signal processing for audio, including a nonlinear psychoacoustic time-invariant DAC effect. It focuses on headphone and binaural audio research.

1 investor

Bioarchitech develops multifunctional cancer immunotherapies derived from viral genetic code, including an intravenous engineered Vaccinia virus therapy (BA-V151) for metastatic cancer and a self-amplifying RNA intratumoural therapy (BA-R166) for early-stage cancers. Its candidates aim to both kill tumour cells and induce anti-tumour immunity, with initial focus on oesophageal and lung cancer.

1 investor

BioAscent provides integrated drug discovery services, including assay development, target analysis, compound screening (including HTS), medicinal and synthetic chemistry, computational chemistry, and compound management with in-house diversity and fragment libraries. It serves pharmaceutical and biotech clients from its site in Newhouse, Scotland.

1 investor

Biocartesian provides optical pooled screening services for functional genomics research. The company uses its proprietary ARADIA technology to link microscopy-based cellular phenotypes with genetic perturbations, enabling researchers to conduct large-scale CRISPR screens and other genomic studies with visual, spatial, and live-cell readouts.

1 investor

BioCell Analytica provides effect-based analysis using cultured cells to detect health- and environment-hazardous contaminants in water, soil, and sediment, capturing the combined "cocktail effect" of multiple substances. It serves the water industry for testing drinking water, wastewater treatment efficiency, and chemical pollution monitoring.

1 investor

Biocellis develops a patented bioluminescence immunoassay platform that delivers laboratory-grade, picogram-level sensitivity with results in under 60 seconds in a compact, portable format for point-of-care and high-throughput screening. Its diagnostics target human health, veterinary, environmental, food safety, and public screening applications across hospitals, clinics, and field settings.</parameter> <parameter name="founders">[{"full_name": "Vincent Poher", "title": "Co-founder", "linkedin_url": "https://www.linkedin.com/in/vincentpoher/"}, {"full_name": "Thierry Rose", "title": "Co-founder", "linkedin_url": "https://www.linkedin.com/in/thierry-rose-122013254/"}, {"full_name": "Sophie Goyard", "title": "Co-founder", "linkedin_url": "https://www.linkedin.com/in/sophie-goyard-968844103/"}]</parameter> <parameter name="hq_city">Grenoble

1 investor

BioClé is a biotechnology company developing a delivery platform based on bacterial extracellular vesicles (bEVs) to improve the stability, bioavailability, and cellular uptake of bioactive compounds.

1 investor

BioCompute is developing DNA-based data storage technology, offering exclusive pilot programs for early access. The company operates in the data storage and biotechnology space.

1 investor

BioCorteX builds a biology-based knowledge graph of microbiome samples (Carbon Knowledge) and a foundational emulator (Carbon Mirror) that models interactions between bacteria, the human immune system, diseases, and drugs to generate insights for drug discovery and development. Its products serve the pharmaceutical and therapeutics industry.

1 investor

Biocytogen (HKEX: 02315) is a global biotechnology company that uses genetically engineered mouse models and its RenMice/RenMab/RenNano fully human antibody platforms to develop therapeutic antibody drugs. It provides antibody discovery, humanized mouse models (e.g. B-NDG, immune checkpoint humanized mice), and preclinical pharmacology and CRO services to biopharma clients worldwide.

1 investor

Bio Design Lab develops biopharmaceuticals using synthetic biology and systems-level genetic and genomic design. Its initial focus is advancing retroviral and lentiviral vector platforms that serve as foundational technologies for cell and gene therapies.

1 investor

Biodimension operates a biofabrication platform that builds reconstructed human tissues, patient-derived organoids, and 3D disease models from ethically sourced human cells for non-animal (NAMs) testing. Its models serve drug discovery, cosmetic safety, and regenerative medicine teams needing regulatory-aligned efficacy and toxicity data without animal testing, from a facility in Bengaluru, India.

1 investor

Biogenera develops DNA-based anti-gene oligonucleotide drugs using PNA (Ag-PNA) to silence altered genes that cause serious diseases, including aggressive pediatric tumors such as neuroblastoma via its BGA002 candidate targeting the MYCN gene. The pharmaceutical biotech company operates its patented MyGenera platform to identify precision-medicine gene therapies for cancers and rare diseases.

1 investor

Biokorf works on 3D Integrated Pharmaceuticals, including particle engineering and cocrystals for drug development.

1 investor

Biolinco provides a platform for cell line development that uses DNA barcoding and multi-omic characterization to help biopharmaceutical companies evaluate and select optimal cell clones. The platform addresses limitations in traditional workflows that evaluate only a small number of clones.

1 investor

BioLM provides AI/ML solutions for protein and DNA analysis, serving researchers and scientists in the biotechnology and synthetic biology sectors with tailored models and APIs.

1 investor

BIOS develops a Universal Neural Interface, a brain-computer interface that connects directly to the peripheral nervous system to enable communication between the brain and robotic limbs or digital devices. Its first application targets individuals with limb loss, with broader potential in prosthetics.

1 investor

Biomimetic develops a bioinspired green-laser nano-texturing process that adds anti-reflective, anti-glare, anti-fogging, and super-hydrophilic properties to glass and crystal surfaces without chemicals. Its Tettix-branded treatments work on borosilicate, soda-lime, alkali-aluminosilicate, and sapphire substrates, and the company coordinates the EU-funded EIC Transition project "GLASS".

1 investor

BioModAI provides an autonomous AI agent that designs molecular biology assays, primers, CRISPR guides, and DNA constructs for research and biotech teams. The agent runs real bioinformatics tools on actual genomic data and delivers publication-ready reports with full audit trails, typically within hours.

1 investor

Bionure develops next-generation therapies using therapeutic RNA, chemical compounds, peptidomimetics, and oligonucleotides to treat rare neurodegenerative and neuro-inflammatory diseases such as ALS, Rett syndrome, ataxia, and Huntington's disease. Founded in 2009, the company works on drugs for the nervous system spanning pre-clinical through Phase II development.

1 investor